focus -WSS

focus

author：entertainment 2025-10-01 02:27:37 - browse：115

Illustration of a doctor and patient. The shadow behind the doctor displays 0s and 1s for artificial intelligence. –– health tech coverage from STAT — Molly Ferguson for STAT

The world’s largest technology companies are racing to build generative AI into every corner of health and medicine.

Microsoft has formed an alliance with the electronic health records vendor Epic to wire the technology into dozens of health software products. Google is infusing it into tools used by hospitals to collect and organize data on millions of patients. Not to be outdone, Amazon has unveiled a service to help build clinical note scribes, and is separately working to embed generative AI in drug research and development.

All of this has unfolded faster than federal regulators could blink — or answer questions about how the technology should be tested and evaluated, whether it will help or hurt patients, and how it will impact privacy and the use of personal data.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： ASCO Daily Recap: CAR

entertainment

WSS

Antivenom research: Lessons from HIV applied in search for universal antidote

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Elevance PBM president out as customers face prescription chaos

Take antibiotics after sex, CDC recommends for certain risk groups

FDA approves Moderna’s RSV vaccine, its second licensed product

Wikipedia

focus

leisure time

Activists slam private health insurers over coverage restrictions

STAT wants to know your pick for a great summer read or listen

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Medical records are filled with copy

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

FDA approval of Sarepta Duchenne genetic therapy gives me hope

BD to buy Edwards patient monitoring unit for $4.2 billion

Activists slam private health insurers over coverage restrictions

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

leisure time

Alabama hospital puts IVF treatments on hold

Antivenom research: Lessons from HIV applied in search for universal antidote

A new initiative will help leaders fight the next pandemic

6 phony surgeries that take placebo to the extreme

Ed Silverman on new gene therapies, biosimilars, coffee, and more

UnitedHealth CEO's Medicaid comments send insurer stocks diving

hotspot

entertainment

hotspot

Wikipedia